Thermo Fisher Scientific Inc. $TMO Shares Sold by Neville Rodie & Shaw Inc.

Neville Rodie & Shaw Inc. lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,017 shares of the medical research company’s stock after selling 9,504 shares during the period. Thermo Fisher Scientific makes up 2.0% of Neville Rodie & Shaw Inc.’s portfolio, making the stock its 13th biggest position. Neville Rodie & Shaw Inc.’s holdings in Thermo Fisher Scientific were worth $27,169,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Capital A Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after buying an additional 66 shares during the last quarter. Caldwell Trust Co acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $696,000. NWF Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $377,000. Reynders McVeigh Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 0.5% in the second quarter. Reynders McVeigh Capital Management LLC now owns 9,710 shares of the medical research company’s stock worth $3,937,000 after purchasing an additional 45 shares in the last quarter. Finally, SevenBridge Financial Group LLC increased its holdings in shares of Thermo Fisher Scientific by 38.3% during the second quarter. SevenBridge Financial Group LLC now owns 4,955 shares of the medical research company’s stock valued at $2,009,000 after purchasing an additional 1,371 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TMO. Citigroup upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and increased their target price for the company from $580.00 to $660.00 in a research report on Thursday. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Argus boosted their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $616.60.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $572.03 on Monday. The stock has a market capitalization of $214.92 billion, a P/E ratio of 33.05, a P/E/G ratio of 4.18 and a beta of 0.90. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The business’s fifty day moving average is $565.86 and its two-hundred day moving average is $492.20. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the previous year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase program on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the sale, the executive vice president directly owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 over the last 90 days. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.